The hormone discovered twice

For decades there was a strain of mouse that ate without stopping and grew to three times a normal weight — the ob/ob mouse, obese from a single recessive mutation nobody could name. A classic experiment hinted at what it meant: stitch an ob/ob mouse into the circulation of a normal one, and the obese mouse ate less and lost weight. Something in normal blood was missing from the fat mouse — a circulating factor that told the brain the body had enough fat. For years it had no name because it had no sequence.

In 1994 Jeffrey Friedman’s lab found the gene by positional cloning and, with it, the hormone (Zhang et al., Nature, 1994). They called it leptin, from the Greek for thin. The ob/ob mouse made a broken version and never heard the signal, so it behaved as though permanently starving. The finding settled a century-old question: fat is not inert ballast. It is an endocrine organ, and leptin is the hormone it uses to report its own size to the brain.

The logic was irresistible. Here was a hormone that reported fat mass and suppressed appetite; give an animal more of it and it lost weight. Within a year, recombinant leptin was shown to melt fat off ob/ob mice, which had none of their own (Halaas et al., Science, 1995). The gene was licensed for a fortune. The expectation, stated plainly at the time, was that leptin would be the hormone that cured human obesity.

It was not. When recombinant leptin was given to ordinary obese adults in a careful dose-escalation trial, the weight loss was modest, highly variable, and bought only at large doses that raised injection-site reactions (Heymsfield et al., JAMA, 1999). The drug that emptied the fat mouse barely moved the fat human. The reason is the single most important fact about leptin, and it is why the hormone had to be understood a second time.

Common obesity is not a state of low leptin. It is a state of high leptin that the brain has stopped listening to — leptin resistance. More fat makes more leptin; the hypothalamus turns its sensitivity down; and pouring in still more of a signal the receiver is already ignoring does almost nothing. Leptin is not a dial you can turn up past its own saturation.

The deeper asymmetry is what reframed the hormone. Evolution never needed a strong brake on getting fat; it needed a powerful alarm for getting thin. So leptin’s most forceful action is in its absence: when stores fall and leptin drops, the body reads famine and mounts the full defense — ravenous hunger, a quieted metabolism, suppressed reproduction. Leptin is a signal of sufficiency whose loudest message is its own disappearance. That is exactly backwards from what a weight-loss drug needs, and it is the same wall the modern GLP-1 drugs run into when people stop them: a body that defends the fat it has.

Leptin’s real triumph came in the mirror-image condition — the one place the hormone is genuinely missing. A handful of children carry loss-of-function mutations in the leptin gene itself: no working leptin at all, relentless hunger, severe obesity from infancy. Give them recombinant leptin and the effect is close to miraculous — appetite normalizes, weight falls, puberty proceeds (Farooqi et al., NEJM, 1999). The same logic extends to generalized lipodystrophy, where people lack the fat tissue that makes leptin; the engineered analog metreleptin is approved for it.

If the wall is resistance, the interesting question becomes whether the brain can be made to listen again — and that is where leptin found an unexpected partner. In leptin-resistant obese rats, the amylin analog pramlintide partially restored the hypothalamus’s responsiveness to leptin, and in a human study the combination of pramlintide and recombinant leptin produced about 12.7% weight loss — more than either agent alone (Roth et al., PNAS, 2008). One hormone re-opening the ear for another is a genuinely different idea from simply pushing harder on one receptor.

That program did not become a product, but the thread runs straight into the present. Amylin is insulin’s forgotten twin, now the busiest axis on the metabolic frontier, and the notion that it can change how the brain reads other satiety signals is part of why. Leptin itself sits one step upstream of the melanocortin appetite circuit that the incretin drugs also act through — the same wiring, approached from a different door.

Leptin is the cleanest cautionary tale in metabolic medicine. A hormone can be real, its biology landmark-grade, its discovery worth a Nobel-tier place in the textbooks — and still not be a drug, because physiology is arranged to resist exactly the thing you want it to do. The first telling made leptin the cure for obesity. The second telling made it the hormone that explains why obesity is so hard to reverse: a body that treats fat loss as an emergency and leptin as the alarm it learns to ignore.

• Leptin proved fat is an endocrine organ. Positional cloning of the ob gene in 1994 identified the circulating factor the obese ob/ob mouse was missing — fat tissue reporting its own size to the brain.
• It was expected to cure obesity, and didn't. Recombinant leptin emptied the fat mouse but barely moved ordinary obese humans in trials — the gap that forced a second understanding of the hormone.
• Resistance, not deficiency, defines common obesity. Obesity runs on high leptin the brain ignores. Adding more of an unheard signal does little; the problem is downstream of the hormone.
• It's a starvation alarm more than a satiety brake. Leptin's strongest effects appear when it falls — driving hunger and conservation. That asymmetry is the opposite of what a weight-loss drug needs.
• Replacement works only where leptin is truly absent. Congenital leptin deficiency and lipodystrophy respond dramatically to leptin/metreleptin. And amylin can partially re-sensitize the brain to it — the thread into the modern amylin era.